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Abstract
Human mesenchymal stromal/stem cells (MSC) isolated from fetal tissues hold promise for use in tissue engineering
applications and cell-based therapies, but their collection is restricted ethically and technically. In contrast, the placenta is a
potential source of readily-obtainable stem cells throughout pregnancy. In fetal tissues, early gestational stem cells are
known to have advantageous characteristics over neonatal and adult stem cells. Accordingly, we investigated whether early
fetal placental chorionic stem cells (e-CSC) were physiologically superior to their late gestation fetal chorionic counterparts
(l-CSC). We showed that e-CSC shared a common phenotype with l-CSC, differentiating down the osteogenic, adipogenic
and neurogenic pathways, and containing a subset of cells endogenously expressing NANOG, SOX2, c-MYC, and KLF4, as well
as an array of genes expressed in pluripotent stem cells and primordial germ cells, including CD24, NANOG, SSEA4, SSEA3,
TRA-1-60, TRA-1-81, STELLA, FRAGILIS, NANOS3, DAZL and SSEA1. However, we showed that e-CSC have characteristics of an
earlier state of stemness compared to l-CSC, such as smaller size, faster kinetics, uniquely expressing OCT4A variant 1 and
showing higher levels of expression of NANOG, SOX2, c-MYC and KLF4 than l-CSC. Furthermore e-CSC, but not l-CSC, formed
embryoid bodies containing cells from the three germ layer lineages. Finally, we showed that e-CSC demonstrate higher
tissue repair in vivo; when transplanted in the osteogenesis imperfecta mice, e-CSC, but not l-CSC increased bone quality and
plasticity; and when applied to a skin wound, e-CSC, but not l-CSC, accelerated healing compared to controls. Our results
provide insight into the ontogeny of the stemness phenotype during fetal development and suggest that the more
primitive characteristics of early compared to late gestation fetal chorionic stem cells may be translationally advantageous.
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Introduction
Mesenchymal stromal/stem cells (MSC), isolated from a range
of adult and fetal tissues, have generated substantial interest for use
in cell therapy and tissue engineering due to their ability to migrate
to sites of injury and regenerate and repair damaged tissues
[1,2,3]. We [4] and others [5,6,7] have shown that human first
trimester fetal MSC present advantages for regenerative medicine
over adult and perinatal MSC, such as faster kinetics, greater
expansion potential, smaller size, unique adhesion molecule
profile, greater telomerase activity and broader differentiation
potential.
First trimester human fetal MSC have now been applied with
significant effect in both hereditary and acquired disease
paradigms. Human fetal blood MSC transplanted in a mouse
model of osteogenesis imperfecta substantially reduced long bone
fracture rates, with donor cells engrafting at sites of bone
formation and differentiating into functional osteoblasts, which
modified bone matrix and reduced bone brittleness [8,9]. Similarly
transplantation of fetal blood MSC in a mouse model of collagen
type 1 deficiency led to improvement of glomerulopathy [10].
Finally tissue-engineered bone grafts seeded with first trimester
bone marrow MSC resulted in closure of critical-sized femoral
defects in rats by promoting woven and compact bone formation
[11].
Collection of fetal blood and somatic tissues in the first
trimester, however is technically challenging and usually requires
pregnancy termination, an obstacle to autologous applications
[12]. For allogeneic applications, the placenta in contrast is larger
and easier to separate than other fetal tissues following pregnancy
termination and hence a more realistic candidate for cell banking.
In terms of supply, first trimester suction termination of pregnancy
is the commonest operation in the world, but remains ethically
contentious as a cell source. However fetal MSC can also be
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isolated in ongoing pregnancies from surplus tissues obtained
during routine prenatal diagnostic procedures such as chorionic
villous sampling [13,14,15] and amniocentesis [16,17,18]. Al-
though amniotic fluid stem cells have therapeutic potential in the
clinic, they are restricted to harvest in the mid-trimester, whereas
the earlier gestational age of chorionic stem cells harvested at 10–
12 weeks should be preferable for autologous prenatal cell therapy
within the window of fetal immunological naivety. First trimester
chorionic stem cells may also be developmentally-advantageous
for allogenic and postnatal autologous use and have already been
expanded large-scale in human serum with substantially more
success than second trimester amniotic fluid stem cells [7].
Although there are substantial reports characterizing amniotic
fluid stem cells, the literature on chorion-derived stem cells is
insufficient with limited characterisation of immuno-phenotype
and a focus primarily on isolation techniques and identification of
their vascular niche within the placenta [13,19,20,21,22]. In
addition many studies of term chorionic cells report cells of both
fetal and maternal origin [22,23], with some groups isolating pure
maternal origin cells only [21,24,25,26], and others failing to
exclude maternal cell origin [19,20,27,28,29,30]. In contrast work
on first trimester chorionic stem cells has shown fetal origin by
karyotyping [13], although not carried out in all studies
[14,15,31]. Notwithstanding this problem of contaminating
decidual maternal stem cells, comparisons of term placenta/
chorionic stem cells with adult bone marrow MSC [22,25] have
indicated that these cells may be more primitive than adult MSC
with evidence of greater self renewal [26], expression of some
pluripotency markers [20,27,29] and potential to differentiate
beyond mesodermal lineages to hepatogenic [28] and neurogenic
lineages [15,31].
We compared the phenotype of first trimester and term fetal
placental chorionic stem cells (e-CSC and l-CSC respectively) to
investigate their suitability for cell-based therapies and tissue
engineering applications. Here, we show that compared to l-CSC,
e-CSC are smaller cells with faster growth kinetics, and higher
levels of pluripotency marker expression. We also found that e-
CSC uniquely expressed OCT4A variant 1 and had potential to
differentiate into lineages of the three germ layers in vitro. In
addition e-CSC and l-CSC express markers associated with
primordial germ cells (PGC) and thus may share a developmental
origin with these cells. Finally, we showed that e-CSC demonstrate
higher tissue repair in vivo. Together our results suggest that e-CSC
are more primitive than l-CSC and give insight into the
developmental ontogeny of fetal chorionic stem cells.
Results
e-CSC and l-CSC are of fetal origin
Both e-CSC and l-CSC were isolated based on plastic
adherence and cultured in DMEM supplemented with 10%
FBS. Both populations were c-KIT+ (Fig. 1a), grew in monolayers
and showed a spindle shaped cytoplasm morphology, (Fig. 1b).
The fetal origin of the cells was confirmed by the presence of the
SRY gene in male samples (Fig. 1c). Fluorescence in situ
hybridisation (FISH) analysis showed that all nuclei contained
the X and Y chromosome in both e-CSC and l-CSC populations,
identifying cells as being of fetal origin, with no contaminating
maternal cells (Fig. 1d).
e-CSC are smaller in size with faster growth kinetics than
l-CSC
On average e-CSC were smaller in size than l-CSC
(16.5 mm60.1 s.e.m vs. 24.0 mm60.1, P,0.01; Fig. 2a and 2b).
Kinetic analysis revealed that e-CSC grew faster than l-CSC
(population doubling time 48.6 h63.7 s.e.m vs. 120.7 h627.2,
P,0.05; Fig. 2c) over a longer period of time when maintained at
sub-confluence (17 vs. 11 passages without reduced growth; Fig. 2d)
and generated greater cell numbers when grown beyond
confluence (5.0 PD60.6 s.e.m vs. 2.3 PD61.3 over 288 hours,
P,0.05; Fig. 2e).
e-CSC and l-CSC have osteogenic and adipogenic
differentiation capacity
The e-CSC population showed higher osteogenic potential than
l-CSC, as shown qualitatively by increased intensity of alizarin red
and von kossa staining after culture in osteogenic permissive
conditions for 14 days (Fig. 3a). We used quantitative real time
PCR (primers in Table S2) to semi-quantify the upregulation of
late osteogenic genes and bone matrix related genes in e-CSC and
l-CSC after 2 weeks in vitro differentiation. Relative expression of
each gene was normalized by its expression in non-differentiating
growth medium (basal level) after normalization to GAPDH
(22DDCt). Results showed only differentiated e-CSC expressed
osteocalcin (OC; 5.2%64.6 s.e.m) and differentiated e-CSC
compared to l-CSC had higher expression of osteopontin (OP;
17.5%65.6 vs. 0.3%60.3, P,0.05), bone sialo-protein-II (BSP;
67.8%65.0 vs. 9.7%611.1, P,0.05) and bone morphogenic
protein-2 (BMP2; 7.5%61.2 vs. 0.5%60.3, P,0.01) (Fig. 3b). At
the protein level, collagen type I (COL1) was absent in non-
differentiated cells, but present in differentiated e-CSC and l-CSC
samples, with e-CSC showing 3.2 times more protein (Fig. 3c).
Culture of the cells in adipogenic permissive medium for three
weeks demonstrated that e-CSC produced considerably more Oil
Red O-positive lipid vacuoles than l-CSC (Fig. 3d). Quantification
of adipocyte differentiation regulator peroxisome proliferator-
activated receptor gamma (PPARc) using real time PCR analysis
revealed greater expression in differentiated e-CSC than l-CSC
(P,0.05) (Fig. 3e). Together, these results illustrate the higher
adipogenic potential of e-CSC over l-CSC.
e-CSC and l-CSC differentiate along the neurogenic but
not the hepatogenic lineages
We next investigated the capacity of e-CSC and l-CSC to
differentiate into non-mesodermal lineages. When co-cultured
with C17.2 mouse neural progenitor cells in chemically defined
medium supplemented with Baicalin for 5 days, e-CSC and l-CSC
changed morphology and expressed the neuronal markers b-
tubulin, the microtubule-associated protein 2 (MAP2) and the
NMDA receptor NR1 (Fig. 3f, positive control in Fig. S2a),
indicating that both cell populations have the potential to
differentiate into neural-like cells.
However, culture of e-CSC and l-CSC in hepatic-permissive
medium supplemented with hepatocyte growth factor over 21 days
failed to induce expression of the hepatic markers albumin and
alpha-fetoprotein (AFP) as visualized by confocal immunostaining
(Fig. S1a), with the cells not producing urea in the culture medium
(Fig. S1b).
e-CSC and l-CSC share a common immunophenotype
Both e-CSC and l-CSC share a largely common adhesion
molecule profile, expressing CD11a, CD106, CD51/61, CXCR4,
integrin b3, CD49f, CD49d and aV integrin. However, only e-CSC
expressed CD62P and integrin b7 and, when compared to l-CSC,
e-CSC showed higher levels of CD49b (50.1%63.9 s.e.m vs.
33.0%64.5, P,0.05) and CD49e (81.1%61.1 vs. 67.4%64.2,
P,0.05) (Fig. 4a). Adhesion assays showed that both e-CSC and l-
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CSC exhibited equal adherence to human fibronectin a-chymo-
tryptic 40 kDa (7.5%60.7 s.e.m vs. 9.6%60.4) and 120 kDa
fragments (30.3%69.3 vs. 32.6%66.6), human plasma fibronectin
(34.2%61.0 vs. 48.2%612.2), collagen type I (38.8%68.1 vs.
45.9%65.4), collagen type IV (42.6%69.7 vs. 36.1%65.6),
human placenta laminin (39.8%66.7 vs. 48.1%615.8) and
human VCAM-1 (42.9%69.4 vs. 18.2%65.8) (Fig. 4b).
Both e-CSC and l-CSC share characteristics with MSC [32]
with absence of endothelial (CD14) and hematopoietic markers
(CD34 and CD45), and expression of MSC-associated markers
CD105, CD73, CD44 and the matrix protein vimentin as well as
CD29 and CD90, although CD29 and CD90 are also found in
human embryonic stem cells (hESC) [33,34] (Fig. 4c). Positive
controls are shown in Fig. S2b.
e-CSC uniquely express OCT4A variant 1 and show higher
levels of pluripotency-associated markers
To avoid false positive detection of OCT4 pseudogenes not
involved in maintaining pluripotency [35,36,37,38], RT-PCR was
performed with OCT4A variant 1 specific primers [35] and results
showed expression in e-CSC, but not l-CSC (Fig. 5a). However,
expression of the other variants of OCT4A was shown in both e-
CSC and l-CSC when primers that also detected OCT4A variants
2 and 3 were used (Fig. 5b). Transcript levels of the other
reprogramming factors SOX2, c-MYC, KLF4 as well as NANOG
were subsequently quantified and showed expression levels were
considerably lower relative to hESC for SOX2 (8.5%61.0 s.e.m
and 4.6%60.5; Fig. 5b) and NANOG (2.5%60.1 and 0.6%60.1;
Fig. 5c). However, expression levels were markedly higher in both
e-CSC and l-CSC respectively relative to those found in hESC for
c-MYC (2,472%6785.9 vs. 556.4%6106.7; Fig. 5d) and KLF4
(2,906%6277.3 vs. 1,940%6305.8; Fig. 5e). When we compared
e-CSC to l-CSC, all five pluripotency markers were expressed at
greater relative levels in e-CSC; OCT4A (P,0.05), SOX2 (P,0.05),
c-MYC (P,0.05), KLF4 (P,0.05) and NANOG (P,0.001).
We next used flow cytometry to determine whether lower
expression in l-CSC was associated with fewer positive cells in the
population than e-CSC. However, both populations contained a
similar sized subset of CD24 positive cells (34.2%63.5 s.e.m vs.
36.0%610.0), a marker of undifferentiated hESC. In addition
CD24 is not found expressed in MSC and hence we have not
referred to the chorionic stem cells as MSC [33,39]. As well as
CD24, a subpopulation of cells positive for OCT4A (63.1%65.1
s.e.m vs. 70.2%66.6) were identified in e-CSC and l-CSC
respectively (Fig. 5b).
Both e-CSC and l-CSC also contained a similar sized
subpopulation of cells expressing other markers typical of
undifferentiated hESC [40,41]; SOX2 (62.2%64.2 s.e.m vs.
66.1%63.3), c-MYC (52.3%611.2 vs. 61.6%611.4), SSEA4
Figure 1. e-CSC and l-CSC are of fetal origin. (a) Confocal immuno-fluorescence for c-KIT (b) Cell morphology of early and late gestation
chorionic stem cells (e-CSC and l-CSC respectively) passage 4–5. (c) PCR for Y chromosome specific SRY. Positive and negative controls shown. (d)
FISH analysis for X (FITC) and Y (Texas Red) chromosomes indicated with green and red arrows respectively. 100 cells were counted. All scale bars
100 mm.
doi:10.1371/journal.pone.0043395.g001
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(83.1%68.2 vs. 69.6%622.3), SSEA3 (63.7%66.6 vs.
66.1%63.3), TRA-1-60 (59.4%610.6 vs. 62.8%612.1), TRA-1-
81 (61.8%63.2 vs. 62.8%612.1) (Fig. 6a). Expression and
heterogeneity of the population for OCT4A, SOX2, c-MYC,
SSEA4, SSEA3, TRA-1-60, and TRA-1-81 was confirmed by
confocal immuno-fluorescence. Both e-CSC and l-CSC also
contained a subset of cells expressing KLF4, NANOG and
REX1 (Fig. 6b). Positive controls are shown in Fig. S2c.
e-CSC uniquely form embryoid bodies
To investigate if endogenous expression of pluripotency markers
translates to an ability to differentiate beyond mesodermal
lineages, we tested the capacity of e-CSC and l-CSC to form
embryoid bodies (EBs) in vitro with differentiation to cells from the
three germ layers. We showed that only e-CSC, but not l-CSC,
formed EBs when grown in EB-permissive media, which may be
linked to lack of OCT4A variant 1 expression in l-CSC. The e-CSC
EBs began to form at 3 days and by 12 days were larger in size,
more complex and compact in morphology and presented a
defined peripheral lining (Fig. 7a). EBs from e-CSC expressed
differentiation markers representative of all three germ layers:
Nestin and PAX6 (ectoderm), CK3, CK19 and GATA6 (endoderm),
BMP4 (mesoderm), and SYCP1 (testis) with down regulation of
undifferentiated stem cell marker NANOG (Fig.7b). This was
confirmed by confocal microscopy for Nestin and MAP2
(ectoderm), GATA4 (mesoderm), AFP (endoderm) and laminin,
which was expressed in the peripheral lining of the EBs (Fig. 7c).
Positive controls are shown in Fig. S2d.
e-CSC and l-CSC express markers found in primordial
germ cells
We next investigated the ontogeny of e-CSC and l-CSC
populations. At the transcript level both e-CSC and l-CSC
expressed markers found in primordial germ cells (PGC). These
included c-KIT, a regulator of PGC survival and growth [42,43],
which is expressed in PGC, neural crest stem cells and
haematopoietic stem cells during embryogenesis [44]. However,
e-CSC and l-CSC also expressed other markers which commonly
define PGC: Stella, which is thought to maintain pluripotentiality
[45,46], Fragilis and Nanos3, which have roles in PGC migration
[47,48] as well as SSEA1, an early marker found in PGC and
human embryonic germ (hEG) cells but not hESC [49,50] (Fig. 8a).
Immuno-fluorescence and flow cytometry supported these findings
(positive controls are shown in Fig. S3a). Flow cytometry showed
at the protein level a subpopulation of cells in both e-CSC and l-
CSC respectively positive for STELLA (29%614 and 27%64),
FRAGILIS (32%65 and 38%612), NANOS3 (25%69 and
34%610), SSEA1 (61%61 and 53%64), as well as DAZL
(30%610 and 41%612) and PUM2 (30%68 and 33%614),
which colocalise in hEG cells [51] (Fig. 8b) Representative flow
cytometry images are shown in Fig. S2b. Whereas VASA, a
marker uniquely specific to the germ cell lineage [52], was only
Figure 2. e-CSC are smaller in size and grow faster than l-CSC. (a) Image of cells in suspension used for cell size analysis. (b) Average cell size
in mm of e-CSC (black) and l-CSC (red) when in suspension. (c) Average growth rate in hours taken for cell population to double during exponential
growth phase; i.e. population doubling time (DT). e-CSC (black), l-CSC (red). (d) Cell expansion capacity over 1500 hours measured by average
cumulative population doublings (Cumulative PD) of e-CSC (m) and l-CSC (.) when passaged at sub-confluence. (e) Cell kinetics measured by
average cumulative population doublings of e-CSC (m) and l-CSC (.) when seeded at low density and grown beyond confluence for 288 hours.
* P,0.05; ** P,0.01, Student’s t test, n=3 different samples per cell group. Mean 6 s.e.m. All scale bars 100 mm.
doi:10.1371/journal.pone.0043395.g002
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detected in e-CSC and not l-CSC at the transcript level (Fig. 8b),
flow cytometry showed a small proportion of cells expressed VASA
in both e-CSC and l-CSC (25%610 and 17%65 respectively).
Also only a small proportion of e-CSC and l-CSC respectively
expressed TNAP, used to denote early PGC [53,54] (20%612 and
22%614) and BLIMP1, not found in hEG cells [55], but a key
marker in PGC that prevents dedifferentiation into pluripotent
stem cells [56] (13%61 and 15%61). Down-regulation of Blimp1
in e-CSC and l-CSC may be responsible for the high expression
levels of its targets c-MYC and KLF4, which were at least five times
higher than expressed by hESC (Fig.5). PGC reside in extra-
embryonic tissues prior to migration along the genital ridge where
they undergo epigenetic reprogramming including erasure of
methylation on H19 [57,58]. To determine to which develop-
mental stage of PGC e-CSC and l-CSC are most similar, we
investigated the methylation status of H19. We found H19 was
both hypermethylated and unmethylated in both e-CSC (50%60
hypermethylated and 50%60 unmethylated, n = 3) and l-CSC
(70%68 hypermethylated and 30%68 unmethylated, n= 3)
(Fig. 8c), indicating that e-CSC and l-CSC may contain cells or
primordial origin which have been retained in placental tissue
prior to the start of genital ridge migration, at a time when imprint
erasure has not yet started.
e-CSC showed greater tissue repair capacity in vivo
compared to l-CSC
We first compared the capacity of e-CSC and l-CSC to improve
bone pathology in a mouse model of osteogenesis imperfecta (oim
mice). Oim mice suffer from bone brittleness in response to a
mutation in the collagen Type I alpha 2 gene [8,9]; e-CSC and l-
CSC (106 cells in PBS) were transplanted intraperitoneally into oim
neonates (n = 15 per transplanted group and n=30 for non-
transplanted oim) and culled 8 weeks later for analysis. Transplan-
tation of e-CSC led to an improvement of overall bone quality, i.e.
total work (0.90 mJ60.09 s.e.m for non-transplanted oim mice vs.
1.86 mJ60.42 for e-CSC-transplanted oim mice, P,0.01) (Fig. 9a)
and bone plasticity, i.e. work from yield to fracture (0.62 mJ60.08
s.e.m for non-transplanted oim mice vs. 1.54 mJ60.40 for e-CSC-
transplanted oim mice, P,0.01) (Fig. 9b), whilst oim mice
transplanted with l-CSC did not show any significant improve-
ments (1.16 mJ60.14 for total work, and 0.89 mJ60.12 for work
from yield to fracture) (Fig. 9a and 9b). The differences in bone
parameters between oim mice transplanted with e-CSC and l-CSC
were likely to result from differences in intrinsic donor cell
properties, as we observed no difference in donor cell engraftment
between e-CSC and l-CSC for both bone marrow (BM) and bone
(Fig. S4).
Figure 3. Osteogenic, adipogenic and neurogenic differentiation of e-CSC and l-CSC. (a) Alizarin red staining (calcium deposits) and von
kossa staining (mineralisation) of cells grown in osteogenic permissive media for 2 weeks. (b) Quantitative real time PCR of fold increased expression
of osteogenic genes after osteogenic differentiation; osteopontin (OP), procollagen endopeptidase enhancer (PCE), osteocalcin (OC), osterix (OSX),
bone sialo-protein-II (BSP) and bone morphogenic protein-2 (BMP2). (c) Western blot of COL1 for e-CSC and l-CSC not differentiated (non-diff) and
differentiated to bone for 2 weeks (diff). Positive and negative controls shown. Loading control is b-actin. (d) Oil Red O staining (lipid droplets) of e-
CSC and l-CSC grown in adipogenic permissive media for 3 weeks. (e) Quantitative real time PCR of fold increased expression of adipocyte
differentiation regulator peroxisome proliferator-activated receptor gamma (PPARc). (f) Morphology and expression of neuronal markers b-TUBULIN,
MAP2 and NMDA receptor NR1 shown with FITC (green) of e-CSC and l-CSC after 5 days neurogenic differentiation. Nuclei stained with DAPI (blue).
All quantitative real time PCR data normalised to GAPDH and basal expression levels of differentiation genes (i.e. 22DDCt). e-CSC (black) and l-CSC
(red). Data. * P,0.05; ** P,0.01, Student’s t test, n= 3 per cell group. Mean 6 s.e.m. All scale bars 100 mm.
doi:10.1371/journal.pone.0043395.g003
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We next compared the tissue repair capacity of e-CSC and l-
CSC during the skin wound healing process. Full thickness dermal
excision skin wounds were treated with local application of either
e-CSC or l-CSC in PBS or PBS alone (n= 8 per group).
Morphological analysis of H&E sections of the wound beds seven
days later showed that the healing process for the e-CSC-treated
wounds was more advanced than for either PBS or l-CSC-treated
wounds. It was evident by a lower number of infiltrated cells in the
e-CSC-treated wounds compared to PBS-treated wounds (53 cells
6 3 s.e.m vs. 66 cells 6 4, respectively, calculated in a 100 mm2
surface, P,0.05). In contrast, l-CSC-treated wounds did not
significantly differ from the controls (70 cells 6 6) (Fig. 9c and 9d).
Similarly, the epithelial thickness of the wound beds was thinner
for the wounds covered with e-CSC compared to controls (46 mm
6 7 s.e.m vs. 76 mm 6 5, respectively, P,0.01), whilst l-CSC-
treated wounds did not significantly differ from the controls
(81 mm611) (Fig. 9c and 9e).
Discussion
Identifying a safe, suitable and readily obtainable supply of
therapeutic cells is a major challenge in regenerative medicine.
Our work compares two potential candidates; first trimester and
term human placental chorionic stem cells (e-CSC and l-CSC
respectively), available from discarded tissues after first trimester
chorionic villous sampling or termination of pregnancy, or after
delivery. We derived pure populations of cells of fetal not maternal
origin to show that e-CSC offer advantages relevant to the clinic
when compared with their term counterparts.
Here we showed that e-CSC and l-CSC could differentiate
down the osteogenic and adipogenic pathways, as well as
neurogenic pathways, as previously reported [31], although they
failed to differentiate down the hepatogenic lineage. Both
populations shared a common immunophenotype and adhesion
molecule profile, both expressing pluripotency markers as well as
markers associated with PGC at the transcript and protein levels.
However, e-CSC had a smaller size, higher kinetics and longer
self-renewal potential, and showed greater osteogenic and
adipogenic differentiation qualitatively at the whole population
level. e-CSC also expressed pluripotency markers at higher levels
than l-CSC, formed embryoid bodies in vitro, and expressed the
variant 1 transcript of the OCT4A isoform, critical for pluripotency
[35,36,37,38]. In addition, relevant to cell-based therapy, we
showed that e-CSC have higher tissue repair potential in vivo when
transplanted neonatally into osteogenesis imperfecta mice, or applied
locally to a dermal excision skin wound. This might be due to
superior lineage specific differentiation and/or greater paracrine
effects of e-CSC compared to l-CSC. This suggests e-CSC are
more primitive than l-CSC and we therefore postulate that the
phenotype of stem cells isolated from placental chorionic tissue
evolves during pregnancy, with a decrease in plasticity paralleling
a down regulation of expression levels of early ‘‘stemness’’ genes.
Our findings parallel our previous work, which showed fetal
bone marrow MSC in contrast to their adult counterparts were
smaller, grew faster and senesced later, despite sharing a common
Figure 4. e-CSC and l-CSC have a similar immunophenotype. (a) Flow cytometry for percent of e-CSC (black) and l-CSC (red) populations
positive for surface adhesion markers; CD62P, Integrin b7, CD11a, CD106, CD51/61, CD49b, CXCR4, Integrin b3, CD49f, CD49d, aV Integrin and CD49e.
(b) Percentage of e-CSC (black) and l-CSC (red) populations that adhered to fibronectin a-chemotryptic 40 kDa (Fn 40 kDa), fibronectin a-
chemotryptic 120 kDa (Fn 120 kDa), whole fibronectin (Fn), collagen I (col I), collagen IV (col IV), human placenta laminin (laminin) and vascular cell
adhesion molecule-1 (VCAM-1). Negative control DMEM alone (media). Data. * P,0.05, Student’s t test, n=3 per cell group. Mean 6 s.e.m. (c)
Confocal immuno-fluorescence for endothelial marker (CD14), hematopoietic markers (CD34 and CD45), MSC-associated markers (CD105, CD73 and
CD44), matrix protein (vimentin) and markers found in pluripotent cells as well as MSC (CD29 and CD90) stained with FITC (green). Nuclei stained with
DAPI (blue). Scale bar 100 mm. Positive controls are shown in Fig. S3a.
doi:10.1371/journal.pone.0043395.g004
Human Fetal Placental Chorionic Stem Cells
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e43395
immunophenotype with expression of mesenchymal, adhesion and
lineage markers in the whole population [4]. Others have
previously reported that early placental MSC or e-CSC [13] have
increased proliferative potential when compared to adult bone
marrow MSC. Our data indicate that human fetal chorionic stem
cells retain their immunophenotype with age, but lose associated
primitive characteristics, not only from fetal to adult, but also from
fetal to neonatal.
The absence of OCT4A variant 1 expression in l-CSC at the
transcript level and downregulation of other pluripotency markers
may be pivotal to the decline of primative characteristics seen in
these cells when compared to their early gestational counterparts.
OCT4A variant 1 transcript is expressed in the nuclei of
undifferentiated hESC, embryonal carcinoma (EC) cells and
PGC and is responsible for maintaining ‘‘stemness’’, whilst the
other pseudogenes are found in the cytoplasm and have no known
function [36,37,38]. In particular the lack of OCT4A variant 1 in l-
CSC may explain the inability of l-CSC to form embryoid bodies
(EBs) as OCT4A variant 1 is critical to retain pluripotentiality
[35,36]. From a technical view, OCT4A was detected at the
protein level in the nuclei of both e-CSC and l-CSC using
OCT4A-specific antibodies; however the available antibodies may
not be specific for variant 1, potentially also binding to variants 2
and 3 [35]. This was confirmed through investigation of the gene
expression of all OCT4A variants, which were found expressed in
both e-CSC and l-CSC. Therefore the difference between both
populations is only at the level of OCT4A variant 1 expression.
Although OCT4A variant 1 was not detectable in l-CSC, other
pluripotency associated markers were found in both e-CSC and l-
CSC populations at both the transcript and protein level. Of
particular, note both cell populations contained a similar
proportion of cells expressing these markers, indicating down
regulation with increased gestational age rather than a reduced
number of cells expressing these early developmental markers. A
Figure 5. e-CSC have higher expression of pluripotency genes than l-CSC. (a) RT-PCR for OCT4A variant 1. GAPDH and positive and negative
controls shown. (b–f) Quantitative real time PCR for (b) OCT4A all variants, (c) NANOG, (d) SOX2, (e) CMYC and (f) KLF4 for e-CSC (black) and l-CSC
(red) as percentage expression of human embryonic stem cells (hESC). * P,0.05; *** P,0.001, Student’s t test, n= 4 per cell group. Mean 6 s.e.m.
doi:10.1371/journal.pone.0043395.g005
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similar result has been shown in amniotic epithelium stem cells,
whereby expression of NANOG and SOX2 was higher in first
trimester amnion than term, although levels of OCT4 were
unchanged [6]. While there is little literature on this in human
chorionic stem cells [59], work to date on whole chorion tissues
indicates a down regulation of telomerase activity over gestation,
supporting the decline of primative stem cell characteristics with
age in this tissue [60].
Despite both e-CSC and l-CSC expressing early developmental
markers, only e-CSC formed EBs, which we validated with typical
morphology and expression of markers from the three germ layers.
However, the lack of EB formation by l-CSC does not rule out the
potential of these cells to differentiate beyond mesodermal
lineages. Here we showed both e-CSC and l-CSC differentiated
down the neurogenic lineage, but failed to differentiate down the
hepatogenic lineage in our study. Others have shown stem cells
isolated from both early and term placental tissue can form neural
progenitors [13,15,31], cardiomyocytes [61,62,63], hepatocytes
[28,64] and pancreatic cells [65]. Results in a number of studies,
mainly those on term placental stem cells, may be confounded by
contamination with or overgrowth of maternal/decidual cells [23],
as verified in some by characterising the cells [21,22,24,25,26] and
not tested for in others [14,15,19,20,27,28,29,30,31]. Here we
confirmed cells were of fetal origin with no contaminating
maternal cells.
The potential of fetal derived MSC for use in bone tissue
engineering is promising [3] as is their use for cell therapy in bone
related disorders such as brittle bone disease [8,66]. There is
however, limited work on placenta-derived stem cells. Surbek’s
group showed both first trimester and term chorionic stem cells
were capable of generating osteogenic grafts [67], indicating the
potential of these cells in regenerative medicine. Furthermore,
another study showed engraftment of term placental adherent cells
inhibited growth of multiple myeloma in bone and stimulated
bone formation in an immune-deficient model of medullary
myeloma bone disease [68]. Notwithstanding this, neither study
excluded a maternal origin for the cell populations used.
This work offers support for Kucia et al’s [69,70] hypothesis
that cells isolated from adult and fetal tissues that have
pluripotency characteristics may share an origin with PGC. This
has been shown for murine fetal liver and adult bone marrow
derived very small embryonic-like (VSEL) cells [71], and may also
be true for umbilical cord blood VSEL cells [72] as well as human
fetal bone marrow and lung stem cells [73,74]. During fetal
development PGC reside at the junction between embryonic and
extra-embryonic tissues, then migrate through the primitive streak
Figure 6. e-CSC and l-CSC contain a subpopulation positive for pluripotency markers. (a) Representative flow cytometry (n= 3) for
percent of cells positive for CD24, OCT4, SOX2, CMYC, SSEA4, SSEA3, TRA-1-60 and TRA-1-81 in e-CSC and l-CSC whole populations (isotype control in
black). (b) Representative confocal immunofluorescence images for OCT4, SOX2, KLF4, NANOG, REX1, SSEA4, SSEA3, TRA-1-60 and TRA-1-81 stained
with FITC (green). Positive cells indicated with green arrow, negative cells with white arrow. Nuclei stained with DAPI (blue). Scale bar 25 mm. Positive
controls are shown in Fig. S3b.
doi:10.1371/journal.pone.0043395.g006
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to give rise to extra-embryonic mesoderm [75]. Erasure of H19
methylation occurs during PGC migration. As we have demon-
strated e-CSC and l-CSC maintained both methylated and
unmethylated regions on H19 and expressed a wide array of
markers associated with pre-migratory PGCs (OCT4, c-KIT,
STELLA, FRAGILIS, NANOS3) [76,77]. The cells may orginate
from PGCs deposited in the extra-embryonic tissues before
migration and hence before methylation was erased.
Notwithstanding this, we also showed that e-CSC and l-CSC
contain a subfraction of cells expressing post-migratory PGC
markers (VASA, DAZL) [76,77], although VASA transcripts were
not detected in l-CSC. Placental stem cells are known to reside in a
vascular niche [19], therefore these cells may have been deposited
later in PGC development following their mobilisation into the
peripheral blood as shown for VSELs [78].
Human chorionic stem cells are relatively easy to isolate, can be
sourced from surplus tissues at routine prenatal diagnostic
procedures or after term delivery and thus used without ethical
restrictions in allogeneic and autologous applications [79]. Steps
towards establishing the safety of e-CSC and l-CSC for use in the
clinic are already underway. No adverse clinical signs were seen
after administration of allogeneic term placenta derived stem cells
in NOD/SCID mice [80] or when delivered by intramuscular
injection to mice with critical limb ischemia [81]. Furthermore
term placenta cells were safely infused in a patient with acute
myeloid leukemia [25], and are currently in Phase III clinical trials
by Israel’s Pluristem Therapeutics for patients with critical limb
ischemia and peripheral artery disease [82], although maternal
origin of these cells is possible. Transplantation of e-CSC into
immunocompromised mice did not cause tumour formation and
cells repopulated depleted hematopoietic tissues [14], while neural
Figure 7. e-CSC uniquely form embryoid bodies (EBs). (a) Phase contrast image of e-CSC EBs at day 3 and day 12. Scale bar 100 mm. (b) RT-PCR
for expression of NANOG, NESTIN, PAX6, CK3, CK19, GATA6, BMP4, SYCP1 and GAPDH in e-CSC EBs. (c) Confocal immuno-fluorescence of e-CSC EBs
for expression of NESTIN, MAP2, GATA4, AFP and LAMININ stained with FITC (green). Nuclei stained with DAPI (blue). Scale bars 25 mm. Positive
controls are shown in Fig. S3c.
doi:10.1371/journal.pone.0043395.g007
Figure 8. e-CSC and l-CSC express markers found in primordial germ cells. (a) RT-PCR for expression of c-KIT, STELLA, FRAGILIS, NANOS3,
SSEA1, VASA and GAPDH. (b) Flow cytometry for percent of e-CSC (black) and l-CSC (red) populations positive for STELLA, FRAGILIS, NANOS3, SSEA1,
DAZL, PUM2, VASA, TNAP and BLIMP1. (c) DNA methylation status of imprinted gene H19 as percent total input DNA hypermethylated (black),
unmethylated (light grey) and intermediately methylated (dark grey). n=3 per cell group.
doi:10.1371/journal.pone.0043395.g008
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Figure 9. e-CSC showed better tissue repair capacity in vivo compared to l-CSC. (a) Mechanical 3-point bending data in a mouse model of
bone brittleness (oim) for overall bone quality shown by total energy input in millijoules to fracture and for (b) femoral plasticity shown by energy
input in millijoules from yield to fracture. Results shown per mouse for non-transplanted oim (blue) and oim transplanted with e-CSC (black) and l-CSC
(red). (c) Cross-section of skin wounds 7 days after 4 mm dermal biopsy in mice treated with either PBS alone (Control) or transplanted with e-CSC or
l-CSC; stained with haematoxylin and eosin. Indicated is collagen (white arrow), granulated cells (black arrow) and epithelial thickness (dashed line). In
the same model of wound repair, (d) number of granulated cells in the wound bed (per 100 mm2) and (e) epithelial thickness across wound in mm.
Data. * P,0.05; ** P,0.01, n.s. (not significant), Student’s t test. Mean 6 s.e.m.
doi:10.1371/journal.pone.0043395.g009
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progenitors derived from e-CSC engrafted in the brain of an
animal model with hypoxia-ischaemia and improved motor
activity [83]. Consequently both e-CSC and l-CSC are emerging
as a safe cell source for allogeneic or autologous cell therapy and
tissue engineering with potential for cell or tissue banking [13,15].
Here we have shown e-CSC have a comparable immunophe-
notype and developmental origin to l-CSC, but have advantages
for use in regenerative medicine, which may be linked to their
earlier state of stemness. Accordingly e-CSC represent a promsing
cell choice for experimental and clinical applications.
Materials and Methods
Cell isolation and culture
Human early and term chorionic stem cells (e-CSC and l-CSC
respectively) were isolated fresh after first trimester chorionic
villous sampling (n = 5, 8+3 to 12+0 weeks gestational age) and term
placenta from caesarean section deliveries (n = 5). The chorionic
tissue (5 cm2 for l-CSC and the totality of the sample for e-CSC)
was separated from the amnion, minced mechanically, and
trypsinized using 0.05% trypsin EDTA (Invitrogen) for 20 min.
Cells were subsequently centrifuged (5 min at 1500 rpm), counted
and replated (104 cells per cm2) in Dulbecco’s modified Eagle’s
medium (DMEM-LG) (Invitrogen)+10% fetal bovine serum
(BioSera). Isolated cells were plastic adherent and cKIT+. All
cells were used at passage 4–8. Ethical approval was given by the
Research Ethics Committees of Hammersmith & Queen Char-
lotte’s Hospitals and the joint University College London
Hospitals. Committees on the Ethics of Human Research (08/
H0714/87).
Bone repair mouse model
All experimental protocols complied with UK Home Office
guidelines. Heterozygous male and female (B6C3Fe a/a-Co-
l1a2oim/Col1a2oim) mice (Jackson Laboratory) were housed in
individual ventilated cages (IVC) in 12:12-hour light dark cycle
(21uC) with water and chow. Offspring were genotyped by
sequencing the oim fragment then homozygous and wild type
colonies established. Homozygous oim mice showed multiple
fractures and brittle bones [8,9,84]. Progeny were weaned at
3061 day and culled at 8 weeks of age. Human e-CSC and l-CSC
were injected intraperitoneally (106 cells in 10 ml PBS) in
homozygous oim neonates 3–4 days after birth. The mice were
weighed and culled at 8 weeks of age for bone analysis. Three-
point bending tests were performed on 8 week old unfractured
frozen and thawed femurs in a materials testing machine (5866
Instron) at a loading rate of 50 mm/s on two supports 9 mm apart
until fracture at mid-diaphysis. Force deflection curves were
analyzed with a custom program (Matlab, MathWorks) to measure
the bending stiffness (slope of the linear elastic deformation), the
yield force (limit between the elastic and plastic deformation), the
ultimate force (maximum force sustained), the total work to
fracture (total area under the curve) and the plastic work to
fracture (area under the curve from the yield point to fracture).
Donor cell engraftment: Femurs from transplanted 8 week old
oim were dissected and bone marrow flushed. Human donor cell
engraftment was determined as previously published [8], RNA was
extracted using TRIzol (Invitrogen) followed by cDNA synthesis
and qRT-PCR (protocol as above) then amplification of both
human specific and human-mouse unspecific sequences of b-actin
gene (See Table S2 for primers). Human:mouse chimerism was
estimated as a ratio using 22DCt. Samples were considered positive
for engraftment with a human-specific b-actin Ct above 35 at a
threshold of 0.13 DRn (primer specificity was confirmed by
absence of amplification of non-transplanted mouse cDNA).
Wound healing model
All experimental protocols complied with UK Home Office
guidelines. C57/Bl6 mice were housed in individual ventilated
cages (IVC) in 12:12-hour light dark cycle (21uC) with water and
chow. Mice were given a dermal excision as previously described
by us [85]. After hair removal from the dorsal surface, 4-mm full-
thickness excisional dermal wounds were made under anaesthesia.
Each mouse was given two dermal excisions on each dorsal side.
Stem cells (e-CSC and l-CSC, 106 cells in 30 ml PBS) were applied
to the left-side wounds and PBS alone applied to the right-side
wounds, to avoid inter-mouse variability. Seven days later, the
mice were culled and the dermal tissues excised, cut across the
middle of the wound and fixed overnight in 10% neutral buffered
formalin at 4uC and embedded in paraffin, sectioned and
subjected to hematoxylin and eosin staining for histological
analysis.
DNA extraction and PCR
Male gender of cells was determined by DNA extraction using
TRIzol (Invitrogen), followed by ethanol precipitation, washing
and DNA dissolution in 8 mM NaOH. Then PCR was performed
in the presence of dNTPs (Promega) and Taq polymerase (Bioline)
with SRY specific primers (see Supplementary Table S2), followed
by gel electrophoresis on 1.5% agarose with ethidium bromide
(Sigma).
FISH analysis
No contamination by maternal cells was confirmed at passages
3–9 for SRY positive samples using XY FISH analysis. Cells were
fixed on slides as previously described [4], then digested with
proteinase K before hybridization with human specific centro-
meric mixture probe (CEP X/Y/18) according to manufacturer’s
protocol (Vysis). Nuclei were counterstained with DAPI and
viewed on a fluorescence confocal laser scanning microscope Leica
TCS SP5 (X600 PL APO oil objective). A total of 100 cells per
group were analysed.
Cell Size
Size of passage 4–5 cells in suspension was determined using
Image J software and calibrated with a haemocytometer.
Growth Kinetics
Cells were plated in triplicate at 16104/cm2 and counted in
trypan blue to exclude dead cells in a haemocytometer either twice
weekly over 60 days with passaging to maintain sub-confluence or
every 2 days for 12 days without passaging. Doubling time (DT)
was calculated via the formula: DT= t/(Log2[y/m]), with t = time
in culture, y = number of cells at end of culture, m=number of
cells at beginning of culture.
Flow cytometry
For intracellular FACS staining cells were detached, blocked
with 1% bovine serum albumin (BSA; Sigma) in phosphate-
buffered saline (PBS; Invitrogen) then fixed with 0.01% parafor-
maldehyde (PFA) (Sigma) and permeabilized with 0.5% Triton X-
100 (Sigma). For cell surface and intracellular FACS staining
detached cells were blocked with 1% BSA and incubated with
specific anti-human primary antibodies (see Table S1), either
conjugated with PE, FITC or PE-Cy5 or unconjugated. For
unconjugated antibodies, cells were subsequently washed with 1%
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BSA and incubated with secondary goat anti-murine IgM PE
(Santa Cruz). All samples were analyzed in triplicate by
FACScalibur flow cytometry (Becton Dickinson). Positive controls
were hESC and negative controls were IgG or IgM primary
antibody-specific isotype controls.
RNA extraction and cDNA synthesis
Total RNA was extracted from cells using RNeasy mini RNA
isolation kit (Qiagen) followed by cDNA synthesis using Pd(N)6
random hexamers and M-MLV reverse transcriptase in the
presence of dNTPs (Promega) (10 min, 25uC; 60 min, 42uC and
10 min, 75uC).
RT-PCR
Reverse-transcriptase PCR (RT-PCR) was performed with
cDNA using specific primers (see Table S2), dNTPs,610 buffer
and Taq polymerase for 40 cycles according to the manufacturer’s
protocol (Qiagen).
qRT-PCR
Quantitative real time polymerase chain reaction (qRT-PCR)
was performed using SYBR green dye (Applied Biosystem) and
analysed either with MJ-opticon or ABI Prism 7700 Sequence
Detection system (Applied Biosystem). Samples were normalized
against the internal control (GAPDH) and the 22DCt of each sample
plotted (log10 scale) relative to the expression level in human
embryonic stem cells (hESC) line H9 (from Wei Cui), arbitrarily
set to 100. Primers supplied in Table S2.
Fluorescence immunostaining and confocal microscopy
Cells were fixed and stained as previously described [4] and
mounted in VectaShield labelled with DAPI (Vector Labs).
Fluorescence confocal laser scanning microscopy images were
collected on a Leica TCS SP5 (6400 PL APO oil objective) and
transferred to Adobe Photoshop (Adobe Systems). Primary
antibodies are listed in Table S1. Secondary antibodies were
donkey anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch
Laboratories). Positive controls were hESC and negative controls
differentiated cells.
Adhesion Assay
Human plasma Fn (Sigma-Aldrich) or 40 and 120 kDa human
Fn a-chymotryptic fragments (Chemicon ITL), calf skin collagen
type I and human placenta collagen IV (Sigma-Aldrich) were
adsorbed at room temperature (2 hr) at 10 mg/cm2 in PBS.
Recombinant human VCAM-1 (ADP5, R&D Systems) and
human placenta laminin (Sigma-Aldrich) were adsorbed at
1 mg/cm2 in PBS at 4uC similarly. Control plates were coated
with 2% BSA. Coating solutions were aspirated and plates were
incubated with 2% BSA in PBS (30 min) to block non-specific
binding. Plates were washed with PBS before 50,000 cells/cm2
were plated in serum-free medium (DMEM) for 1 hr at 37uC.
Non-adherent cells were removed with PBS and adherent cells
were trypsinised and counted. Percentage of adhesion was
calculated as follows: number of adherent cells/(number of
adherent cells+number of non-adherent cells)*100 [86].
Analysis of H19 methylation
Genomic DNA was extracted using DNeasy Blood and Tissue
Kit (Qiagen) and made free from RNA using RNase A
(Invitrogen). The EpiTect Methyl qPCR assay (Qiagen) was used
to digest DNA with methylation-sensitive and methylation-
dependent enzymes to obtain fractions of unmethylated, partially
methylated and hypermethylated DNA. The methylation status of
H19 was then quantified using qRT-PCR and specific primers (see
Table S2), data were then normalised to the total amount of DNA.
Embryoid body formation and analysis
Undifferentiated e-CSC and l-CSC were induced to differen-
tiate in vitro into EBs by incubating confluent cells with
differentiation medium containing knockout Dulbecco’s modified
eagle’s medium (Gibco BRL Life Technologies) supplemented
with 1 mM L-mercaptoethanol, 1% non-essential amino acids
stock (all Gibco BRL Life Technologies) and 20% FBS (Biosera).
At confluence, cells were incubated with 1 mg/ml type IV
collagenase (Invitrogen) before being dissociated into small clumps
on low attachment Petri dish in differentiating medium and
allowed to develop into EBs for 12 days. EB suspensions were
either pelleted and used for RNA extraction and RT-PCR of
lineage specific markers (see Table S2 for primers) or transferred to
gelatin-coated coverslips before fixation in 4% PFA and analysis
under confocal microscopy for expression of lineage markers from
all three germ layers (see Table S1 for primary antibodies used).
Positive controls were pluripotent-induced human amniotic fluid
stem cell-derived EBs.
Osteogenic Differentiation
Cells were cultured in DMEM supplemented with 10 mM b-
glycerophosphate, 0.2 mM ascorbic acid and 1028 M dexameth-
asone for 14 days. Then cells were fixed with 10% formalin and
stained with von kossa or alizarin red, or pelleted and extracted for
RNA or protein for qRT-PCR or western blot analysis respec-
tively. All analysis was compared to undifferentiated cells. qRT-
PCR reactions were carried out as described above for osteogenic
specific primers (given in Table S2) and normalised to GAPDH and
compared to basal expression levels in non-differentiated cells.
Adipogenic differentiation
Cells were seeded at a concentration of 5000 cells/cm2 on tissue
culture plastic plates and coverslips and cultured in high glucose
DMEM supplemented with 1% penicillin/streptomycin (Invitro-
gen), 2 mM L-glutamine (Invitrogen) and 10% FBS (Biosera Ltd.,
East Sussex, UK) for 1 day. The media were then changed to high
glucose DMEM supplemented with 0.5 mM hydrocortisone,
0.5 mM isobutyl methylxanthine and 60 mM indomethacin (all
Sigma-Aldrich) for 2 weeks. Lipid droplets were subsequently
stained with oil-red-O (Sigma-Aldrich). Oil-red-O was prepared at
a 1% concentration in isopropanol (BDH Laboratory Supplies,
Dorset, UK) then diluted in a 3:2 ratio of stock solution to distilled
water. Cells were washed in PBS, fixed with 10% formalin, rinsed
with 60% isopropanol (BDH Laboratory Supplies), followed by
staining for 10 minutes. The cells were then washed 4 times with
distilled water and photographed using an Olympus CK40-SLP
microscope and an Olympus C3040-ADL camera (Olympus).
Hepatogenic differentiation
Cells were seeded at a concentration of 5000 cells/cm2 on tissue
culture plastic plates and coverslips coated with Matrigel (BD
Biosciences) and cultured in high glucose DMEM supplemented
with 1% penicillin/streptomycin (Invitrogen), 2 mM L-Glutamine
(Invitrogen) and 10% FBS for 3 days. The media were then
changed to high glucose DMEM supplemented with 15% FBS,
1% penicillin/streptomycin, 2 mM L-glutamine, 300 mM mono-
thioglycerol (Sigma), 20 ng/ml hepatocyte growth factor (Pepro-
tech), 10 ng/ml oncostatin M (Peprotech), 1027 dexamethasone
(Sigma), 100 ng/ml FGF4 (Peprotech) and 1X ITS (insulin,
Human Fetal Placental Chorionic Stem Cells
PLOS ONE | www.plosone.org 12 September 2012 | Volume 7 | Issue 9 | e43395
transferrin, selenium, Sigma). The cells were allowed to differen-
tiate for 21 days and then fixed and stored in PBS for
immunofluorescence. The differentiation media were collected
and analysed for the presence of urea secreted by the differentiated
cells. Urea was subsequently measured using the urea/ammonia
determination kit (R-Biopharm AG, Darmstadt, Germany)
according to the manufacturers instructions, with positive control
being urea (as per manufacturer’s instructions) and negative
control undifferentiated e-CSC and l-CSC. Cells were subsquently
assessed for expression of the hepatocyte markers ALBUMIN and
ALPHA FETO-PROTEIN (AFP) using confocal microscopy.
Positive control were HepG2 cells (gift from Wei Cui) and negative
controls were undifferentiated e-CSC and l-CSC cells.
Neurogenic differentiation
Cells were seeded at a concentration of 5000 cells/cm2 on tissue
culture plastic plates and coverslips and cultured in high glucose
DMEM supplemented with 1% penicillin/streptomycin (Invitro-
gen), 2 mM L-glutamine (Invitrogen) and 10% FBS (Biosera Ltd.,
East Sussex, UK) for 1 day. The media were then changed to high
glucose DMEM supplemented with 0.5% FBS, 1% penicillin/
streptomycin, 2 mM L-glutamine and 0.1% baicalin (Sigma),
freshly made. C17.2 mouse neural progenitor cells (from Henrik
Hagberg and Pierre Gressens) were added in a co-culture setting to
promote differentiation, using co-culture membrane inserts
(Thermo Scientific Nunc, Loughborough, UK). The cells were
allowed to differentiate for 5 days and assessed for expression of
the neuronal markers b-tubulin and MAP2 and for the NMDA
receptor NR1 using confocal immunostaining. Positive controls
were differentiated neural progenitors (gift Henrik Hagberg and
from Pierre Gressens) and negative controls were undifferentiated
e-CSC and l-CSC cells.
Protein Extraction and Western Blot
Total protein was extracted using RIPAE buffer containing
protease inhibitor cocktail and PMSF (Sigma). Protein concentra-
tions were determined using the BCA protein assay (Thermo-
scientific), with bovine serum albumin as the standard. Proteins
were run on an 8% SDS-PAGE, transferred to nitrocellulose,
blocked with milk and incubated with primary anitbody COL1A2
(123 kDa) (Abcam). Secondary HRP-linked anti-rabbit IgG (GE
healthcare), followed by enhanced chemiluminescence (Thermo
scientific) was used for detection. Loading control used was b-actin
(Abcam).
Statistical analysis
Data were expressed as mean 6 s.d (standard deviation) or
mean 6 s.e.m (standard error). Parametric statistics were applied
after confirming normal distributions on histograms and unpaired
two-tailed Student’s t-test was used for comparison between
groups. P,0.05 was considered significant.
Supporting Information
Figure S1 e-CSC and l-CSC hepatogenic differentiation. (a)
Confocal immuno-fluorescence for ALBUMIN and AFP in e-CSC
and l-CSC grown in hepatogenic permissive media for 3 weeks.
HepG3 cells used for positive control. All genes stained with FITC
(green). Nuclei stained with DAPI (blue). Scale bars 100 mm. (b)
Presence of urea (mmol/l) in hepatogenic differentiation media
(diff) of e-CSC and l-CSC. Positive (urea; according to the
manufacturer’s instructions) and negative controls; non-differenti-
ated (non-diff) e-CSC and l-CSC are shown. n=4 per cell group.
Data. n.s. (not significant), Student’s t test. Mean 6 s.e.m.
(TIF)
Figure S2 Positive controls for confocal immuno-fluorescence.
(a) Positive controls (differentiated neural progenitors) of neuronal
differentiation for expression of b-TUBULIN, MAP2 and NR1.
(b) Positive controls (human first trimester fetal bone marrow
mesenchymal stem cells, hfMSC) CD105, CD73, CD44, CD29
and CD90 (c) Positive controls (hES cells line H9) OCT4A,
SOX2, KLF4, NANOG, REX1, SSEA4, SSEA3, TRA-1-60, and
TRA-1-81 (d) Positive controls (pluripotent-induced human
amniotic fluid stem cells-derived EBs) NESTIN, MAP2, AFP,
GATA4 and LAMININ. All genes stained with FITC (green).
Nuclei stained with DAPI (blue). Scale bars 50 mm.
(TIF)
Figure S3 e-CSC and l-CSC express PGC associated markers.
(a) Representative confocal immuno-fluorescence for protein
expression of FRAGILIS, SSEA1, TNAP, NANOS3, BLIMP1,
PUM2, STELLA, DAZL and VASA stained with FITC (green).
Nuclei stained with DAPI (blue). Scale bar 100 mm. (b)
Representative flow cytometry for PGC markers; STELLA,
FRAGILIS, NANOS3, SSEA1, DAZL, PUM2, VASA, TNAP
and BLIMP1 (isotype control in black).
(TIF)
Figure S4 Engraftment of e-CSC and l-CSC in 8 week-old
transplanted oim mice. Donor cell engraftment in bone marrow
and bone was calculated as the 22DCt of human specific b-actin
normalised to human-mouse non-specific b-actin and using
quantitative real time PCR in oim mice transplanted with e-CSC
(black) or l-CSC (red).
(TIF)
Table S1 Antibodies used. List of antibodies used for immuno-
fluorescence (IF), flow cytometry (FC) and immuno-histochemistry
(IH).
(DOC)
Table S2 Primers used. List of primers used for RT-PCR and
quantitative real time PCR and EpiTect Methyl qPCR assay.
(DOC)
Author Contributions
Conceived and designed the experiments: PVG. Performed the exper-
iments: GNJ DM TIPI KK MV GBG. Analyzed the data: GNJ.
Contributed reagents/materials/analysis tools: PVG ALD NMF PDC
SJS. Wrote the paper: GNJ PVG.
References
1. Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/
multipotent stromal cells: the state of transdifferentiation and modes of tissue
repair–current views. Stem Cells 25: 2896–2902.
2. Chavakis E, Urbich C, Dimmeler S (2008) Homing and engraftment of
progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 45: 514–522.
3. Zhang ZY, Teoh SH, Hui JH, Fisk NM, Choolani M, et al. (2012) The potential
of human fetal mesenchymal stem cells for off-the-shelf bone tissue engineering
application. Biomaterials.
4. Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM (2007) Human first-
trimester fetal MSC express pluripotency markers and grow faster and have
longer telomeres than adult MSC. Stem Cells 25: 646–654.
Human Fetal Placental Chorionic Stem Cells
PLOS ONE | www.plosone.org 13 September 2012 | Volume 7 | Issue 9 | e43395
5. Zhang ZY, Teoh SH, Chong MS, Schantz JT, Fisk NM, et al. (2009) Superior
osteogenic capacity for bone tissue engineering of fetal compared with perinatal
and adult mesenchymal stem cells. Stem Cells 27: 126–137.
6. Izumi M, Pazin BJ, Minervini CF, Gerlach J, Ross MA, et al. (2009)
Quantitative comparison of stem cell marker-positive cells in fetal and term
human amnion. J Reprod Immunol 81: 39–43.
7. Poloni A, Maurizi G, Serrani F, Mancini S, Discepoli G, et al. (2012) Human AB
serum for generation of mesenchymal stem cells from human chorionic villi:
comparison with other source and other media including platelet lysate. Cell
Prolif 45: 66–75.
8. Guillot PV, Abass O, Bassett JH, Shefelbine SJ, Bou-Gharios G, et al. (2008)
Intrauterine transplantation of human fetal mesenchymal stem cells from first-
trimester blood repairs bone and reduces fractures in osteogenesis imperfecta
mice. Blood 111: 1717–1725.
9. Vanleene M, Saldanha Z, Cloyd KL, Jell G, Bou-Gharios G, et al. (2011)
Transplantation of human fetal blood stem cells in the osteogenesis imperfecta
mouse leads to improvement in multiscale tissue properties. Blood 117: 1053–
1060.
10. Guillot PV, Cook HT, Pusey CD, Fisk NM, Harten S, et al. (2008)
Transplantation of human fetal mesenchymal stem cells improves glomerulop-
athy in a collagen type I alpha 2-deficient mouse. J Pathol 214: 627–636.
11. Zhang ZY, Teoh SH, Chong MS, Lee ES, Tan LG, et al. (2010) Neo-
vascularization and bone formation mediated by fetal mesenchymal stem cell
tissue-engineered bone grafts in critical-size femoral defects. Biomaterials 31:
608–620.
12. Chan J, Kumar S, Fisk NM (2008) First trimester embryo-fetoscopic and
ultrasound-guided fetal blood sampling for ex vivo viral transduction of cultured
human fetal mesenchymal stem cells. Hum Reprod 23: 2427–2437.
13. Poloni A, Rosini V, Mondini E, Maurizi G, Mancini S, et al. (2008)
Characterization and expansion of mesenchymal progenitor cells from first-
trimester chorionic villi of human placenta. Cytotherapy 10: 690–697.
14. Spitalieri P, Cortese G, Pietropolli A, Filareto A, Dolci S, et al. (2009)
Identification of multipotent cytotrophoblast cells from human first trimester
chorionic villi. Cloning Stem Cells 11: 535–556.
15. Portmann-Lanz CB, Schoeberlein A, Huber A, Sager R, Malek A, et al. (2006)
Placental mesenchymal stem cells as potential autologous graft for pre- and
perinatal neuroregeneration. Am J Obstet Gynecol 194: 664–673.
16. De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, et al. (2007)
Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol
25: 100–106.
17. Tsai MS, Lee JL, Chang YJ, Hwang SM (2004) Isolation of human multipotent
mesenchymal stem cells from second-trimester amniotic fluid using a novel two-
stage culture protocol. Hum Reprod 19: 1450–1456.
18. Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschlager M (2003) Oct-
4-expressing cells in human amniotic fluid: a new source for stem cell research?
Hum Reprod 18: 1489–1493.
19. Castrechini NM, Murthi P, Gude NM, Erwich JJ, Gronthos S, et al. (2010)
Mesenchymal stem cells in human placental chorionic villi reside in a vascular
Niche. Placenta 31: 203–212.
20. Bacenkova D, Rosocha J, Tothova T, Rosocha L, Sarissky M (2011) Isolation
and basic characterization of human term amnion and chorion mesenchymal
stromal cells. Cytotherapy 13: 1047–1056.
21. Rus Ciuca D, Soritau O, Susman S, Pop VI, Mihu CM (2011) Isolation and
characterization of chorionic mesenchyal stem cells from the placenta.
Rom J Morphol Embryol 52: 803–808.
22. Soncini M, Vertua E, Gibelli L, Zorzi F, Denegri M, et al. (2007) Isolation and
characterization of mesenchymal cells from human fetal membranes. J Tissue
Eng Regen Med 1: 296–305.
23. In’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM,
Claas FH, et al. (2004) Isolation of mesenchymal stem cells of fetal or maternal
origin from human placenta. Stem Cells 22: 1338–1345.
24. Semenov OV, Koestenbauer S, Riegel M, Zech N, Zimmermann R, et al. (2010)
Multipotent mesenchymal stem cells from human placenta: critical parameters
for isolation and maintenance of stemness after isolation. Am J Obstet Gynecol
202: 193 e191–193 e113.
25. Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, et al. (2009)
Manufacturing of human placenta-derived mesenchymal stem cells for clinical
trials. Br J Haematol 144: 571–579.
26. Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, et al. (2008)
Comparison of human placenta- and bone marrow-derived multipotent
mesenchymal stem cells. Stem Cells Dev 17: 1095–1107.
27. Yen BL, Huang HI, Chien CC, Jui HY, Ko BS, et al. (2005) Isolation of
multipotent cells from human term placenta. Stem Cells 23: 3–9.
28. Kim MJ, Shin KS, Jeon JH, Lee DR, Shim SH, et al. (2011) Human chorionic-
plate-derived mesenchymal stem cells and Wharton’s jelly-derived mesenchymal
stem cells: a comparative analysis of their potential as placenta-derived stem
cells. Cell Tissue Res 346: 53–64.
29. Fariha MM, Chua KH, Tan GC, Tan AE, Hayati AR (2011) Human chorion-
derived stem cells: changes in stem cell properties during serial passage.
Cytotherapy 13: 582–593.
30. Miao Z, Jin J, Chen L, Zhu J, Huang W, et al. (2006) Isolation of mesenchymal
stem cells from human placenta: comparison with human bone marrow
mesenchymal stem cells. Cell Biol Int 30: 681–687.
31. Portmann-Lanz CB, Schoeberlein A, Portmann R, Mohr S, Rollini P, et al.
(2010) Turning placenta into brain: placental mesenchymal stem cells
differentiate into neurons and oligodendrocytes. Am J Obstet Gynecol 202:
294 e291–294 e211.
32. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006)
Minimal criteria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position statement. Cytotherapy 8:
315–317.
33. Lian Q, Lye E, Suan Yeo K, Khia Way Tan E, Salto-Tellez M, et al. (2007)
Derivation of clinically compliant MSCs from CD105+, CD242 differentiated
human ESCs. Stem Cells 25: 425–436.
34. Carpenter MK, Rosler ES, Fisk GJ, Brandenberger R, Ares X, et al. (2004)
Properties of four human embryonic stem cell lines maintained in a feeder-free
culture system. Dev Dyn 229: 243–258.
35. Ryan JM, Pettit AR, Guillot PV, Chan JK, Fisk NM (2011) Unravelling the
Pluripotency Paradox in Fetal and Placental Mesenchymal Stem Cells: Oct-4
Expression and the Case of the Emperor’s New Clothes. Stem Cell Rev.
36. Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ, Andrews PW (2008) OCT4 spliced
variants are differentially expressed in human pluripotent and nonpluripotent
cells. Stem Cells 26: 3068–3074.
37. Lee J, Kim HK, Rho JY, Han YM, Kim J (2006) The human OCT-4 isoforms
differ in their ability to confer self-renewal. J Biol Chem 281: 33554–33565.
38. Pesce M, Scholer HR (2000) Oct-4: control of totipotency and germline
determination. Mol Reprod Dev 55: 452–457.
39. Assou S, Le Carrour T, Tondeur S, Strom S, Gabelle A, et al. (2007) A meta-
analysis of human embryonic stem cells transcriptome integrated into a web-
based expression atlas. Stem Cells 25: 961–973.
40. Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, et al.
(2007) Characterization of human embryonic stem cell lines by the International
Stem Cell Initiative. Nat Biotechnol 25: 803–816.
41. Skottman H, Mikkola M, Lundin K, Olsson C, Stromberg AM, et al. (2005)
Gene expression signatures of seven individual human embryonic stem cell lines.
Stem Cells 23: 1343–1356.
42. De Miguel MP, Cheng L, Holland EC, Federspiel MJ, Donovan PJ (2002)
Dissection of the c-Kit signaling pathway in mouse primordial germ cells by
retroviral-mediated gene transfer. Proc Natl Acad Sci U S A 99: 10458–10463.
43. Hoyer PE, Byskov AG, Mollgard K (2005) Stem cell factor and c-Kit in human
primordial germ cells and fetal ovaries. Mol Cell Endocrinol 234: 1–10.
44. Motohashi T, Aoki H, Chiba K, Yoshimura N, Kunisada T (2007) Multipotent
cell fate of neural crest-like cells derived from embryonic stem cells. Stem Cells
25: 402–410.
45. Bowles J, Teasdale RP, James K, Koopman P (2003) Dppa3 is a marker of
pluripotency and has a human homologue that is expressed in germ cell
tumours. Cytogenet Genome Res 101: 261–265.
46. Payer B, Saitou M, Barton SC, Thresher R, Dixon JP, et al. (2003) Stella is a
maternal effect gene required for normal early development in mice. Curr Biol
13: 2110–2117.
47. Tanaka SS, Yamaguchi YL, Tsoi B, Lickert H, Tam PP (2005) IFITM/Mil/
fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse
primordial germ cell homing and repulsion. Dev Cell 9: 745–756.
48. Tsuda M, Sasaoka Y, Kiso M, Abe K, Haraguchi S, et al. (2003) Conserved role
of nanos proteins in germ cell development. Science 301: 1239–1241.
49. Henderson JK, Draper JS, Baillie HS, Fishel S, Thomson JA, et al. (2002)
Preimplantation human embryos and embryonic stem cells show comparable
expression of stage-specific embryonic antigens. Stem Cells 20: 329–337.
50. Park JH, Kim SJ, Lee JB, Song JM, Kim CG, et al. (2004) Establishment of a
human embryonic germ cell line and comparison with mouse and human
embryonic stem cells. Mol Cells 17: 309–315.
51. Moore FL, Jaruzelska J, Fox MS, Urano J, Firpo MT, et al. (2003) Human
Pumilio-2 is expressed in embryonic stem cells and germ cells and interacts with
DAZ (Deleted in AZoospermia) and DAZ-like proteins. Proc Natl Acad Sci U S A
100: 538–543.
52. Castrillon DH, Quade BJ, Wang TY, Quigley C, Crum CP (2000) The human
VASA gene is specifically expressed in the germ cell lineage. Proc Natl Acad
Sci U S A 97: 9585–9590.
53. MacGregor GR, Zambrowicz BP, Soriano P (1995) Tissue non-specific alkaline
phosphatase is expressed in both embryonic and extraembryonic lineages during
mouse embryogenesis but is not required for migration of primordial germ cells.
Development 121: 1487–1496.
54. McLaren A (2003) Primordial germ cells in the mouse. Dev Biol 262: 1–15.
55. Durcova-Hills G, Tang F, Doody G, Tooze R, Surani MA (2008)
Reprogramming primordial germ cells into pluripotent stem cells. PLoS One
3: e3531.
56. Ohinata Y, Payer B, O’Carroll D, Ancelin K, Ono Y, et al. (2005) Blimp1 is a
critical determinant of the germ cell lineage in mice. Nature 436: 207–213.
57. Arnaud P (2010) Genomic imprinting in germ cells: imprints are under control.
Reproduction 140: 411–423.
58. Hajkova P, Erhardt S, Lane N, Haaf T, El-Maarri O, et al. (2002) Epigenetic
reprogramming in mouse primordial germ cells. Mech Dev 117: 15–23.
59. Sung HJ, Hong SC, Yoo JH, Oh JH, Shin HJ, et al. (2010) Stemness evaluation
of mesenchymal stem cells from placentas according to developmental stage:
comparison to those from adult bone marrow. J Korean Med Sci 25: 1418–
1426.
Human Fetal Placental Chorionic Stem Cells
PLOS ONE | www.plosone.org 14 September 2012 | Volume 7 | Issue 9 | e43395
60. Kyo S, Takakura M, Tanaka M, Kanaya T, Sagawa T, et al. (1997) Expression
of telomerase activity in human chorion. Biochem Biophys Res Commun 241:
498–503.
61. Schmidt D, Mol A, Breymann C, Achermann J, Odermatt B, et al. (2006) Living
autologous heart valves engineered from human prenatally harvested progen-
itors. Circulation 114: I125–131.
62. Weber B, Zeisberger SM, Hoerstrup SP (2011) Prenatally harvested cells for
cardiovascular tissue engineering: fabrication of autologous implants prior to
birth. Placenta 32 Suppl 4: S316–319.
63. Okamoto K, Miyoshi S, Toyoda M, Hida N, Ikegami Y, et al. (2007) ‘Working’
cardiomyocytes exhibiting plateau action potentials from human placenta-
derived extraembryonic mesodermal cells. Exp Cell Res 313: 2550–2562.
64. Shin KS, Lee HJ, Jung J, Cha DH, Kim GJ (2010) Culture and in vitro
hepatogenic differentiation of placenta-derived stem cells, using placental extract
as an alternative to serum. Cell Prolif 43: 435–444.
65. Susman S, Soritau O, Rus-Ciuca D, Tomuleasa C, Pop VI, et al. (2010)
Placental stem cell differentiation into islets of Langerhans-like glucagon-
secreting cells. Rom J Morphol Embryol 51: 733–738.
66. Le Blanc K, Gotherstrom C, Ringden O, Hassan M, McMahon R, et al. (2005)
Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation
in a patient with severe osteogenesis imperfecta. Transplantation 79: 1607–1614.
67. Mohr S, Portmann-Lanz CB, Schoeberlein A, Sager R, Surbek DV (2010)
Generation of an osteogenic graft from human placenta and placenta-derived
mesenchymal stem cells. Reprod Sci 17: 1006–1015.
68. Li X, Ling W, Pennisi A, Wang Y, Khan S, et al. (2011) Human placenta-
derived adherent cells prevent bone loss, stimulate bone formation, and suppress
growth of multiple myeloma in bone. Stem Cells 29: 263–273.
69. Kucia M, Machalinski B, Ratajczak MZ (2006) The developmental deposition of
epiblast/germ cell-line derived cells in various organs as a hypothetical
explanation of stem cell plasticity? Acta Neurobiol Exp (Wars) 66: 331–341.
70. Kucia M, Wu W, Ratajczak MZ (2007) Bone marrow-derived very small
embryonic-like stem cells: their developmental origin and biological significance.
Dev Dyn 236: 3309–3320.
71. Shin DM, Liu R, Klich I, Wu W, Ratajczak J, et al. (2010) Molecular signature
of adult bone marrow-purified very small embryonic-like stem cells supports
their developmental epiblast/germ line origin. Leukemia 24: 1450–1461.
72. Kucia M, Halasa M, Wysoczynski M, Baskiewicz-Masiuk M, Moldenhawer S, et
al. (2007) Morphological and molecular characterization of novel population of
CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human
cord blood: preliminary report. Leukemia 21: 297–303.
73. Hua J, Yu H, Dong W, Yang C, Gao Z, et al. (2009) Characterization of
mesenchymal stem cells (MSCs) from human fetal lung: potential differentiation
of germ cells. Tissue Cell 41: 448–455.
74. Hua J, Pan S, Yang C, Dong W, Dou Z, et al. (2009) Derivation of male germ
cell-like lineage from human fetal bone marrow stem cells. Reprod Biomed
Online 19: 99–105.
75. Donovan PJ (1998) The germ cell–the mother of all stem cells. Int J Dev Biol 42:
1043–1050.
76. Saiti D, Lacham-Kaplan O (2007) Mouse Germ Cell Development in-vivo and
in-vitro. Biomark Insights 2: 241–252.
77. Hayashi K, de Sousa Lopes SM, Surani MA (2007) Germ cell specification in
mice. Science 316: 394–396.
78. Ratajczak MZ, Liu R, Marlicz W, Blogowski W, Starzynska T, et al. (2011)
Identification of very small embryonic/epiblast-like stem cells (VSELs)
circulating in peripheral blood during organ/tissue injuries. Methods Cell Biol
103: 31–54.
79. Abdulrazzak H, Moschidou D, Jones G, Guillot PV (2010) Biological
characteristics of stem cells from foetal, cord blood and extraembryonic tissues.
J R Soc Interface 7 Suppl 6: S689–706.
80. Ramot Y, Meiron M, Toren A, Steiner M, Nyska A (2009) Safety and
biodistribution profile of placental-derived mesenchymal stromal cells (PLX-
PAD) following intramuscular delivery. Toxicol Pathol 37: 606–616.
81. Prather WR, Toren A, Meiron M, Ofir R, Tschope C, et al. (2009) The role of
placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical
limb ischemia. Cytotherapy 11: 427–434.
82. Trounson A, Thakar RG, Lomax G, Gibbons D (2011) Clinical trials for stem
cell therapies. BMC Med 9: 52.
83. Park S, Koh SE, Maeng S, Lee WD, Lim J, et al. (2011) Neural progenitors
generated from the mesenchymal stem cells of first-trimester human placenta
matured in the hypoxic-ischemic rat brain and mediated restoration of
locomotor activity. Placenta 32: 269–276.
84. Jones GN, Moschidou D, Lay K, Abdulrazzak H, Vanleene M, et al. (2012)
Upregulating CXCR4 in human fetal mesenchymal stem cells enhances
engraftment and bone mechanics in a mouse model of osteogenesis imperfecta.
Stem Cells Translational Medicine 1: 70–78.
85. Rajkumar VS, Shiwen X, Bostrom M, Leoni P, Muddle J, et al. (2006) Platelet-
derived growth factor-beta receptor activation is essential for fibroblast and
pericyte recruitment during cutaneous wound healing. Am J Pathol 169: 2254–
2265.
86. Huygen S, Giet O, Artisien V, Di Stefano I, Beguin Y, et al. (2002) Adhesion of
synchronized human hematopoietic progenitor cells to fibronectin and vascular
cell adhesion molecule-1 fluctuates reversibly during cell cycle transit in ex vivo
culture. Blood 100: 2744–2752.
Human Fetal Placental Chorionic Stem Cells
PLOS ONE | www.plosone.org 15 September 2012 | Volume 7 | Issue 9 | e43395
